OVARIAN-CANCER - THE PROGNOSTIC VALUE OF THE SERUM HALF-LIFE OF CA125 DURING INDUCTION CHEMOTHERAPY
OVARIAN-CANCER - THE PROGNOSTIC VALUE OF THE SERUM HALF-LIFE OF CA125 DURING INDUCTION CHEMOTHERAPY
复制标题
DOI：
10.1016/0090-8258(88)90244-2
复制
发表时间：
1988-07-01
影响因子：
4.7
通讯作者：
STOTER, G
中科院分区：
文献类型：
--
作者：
VANDERBURG, MEL;LAMMES, FB;STOTER, G
对85例卵巢上皮癌患者进行了研究，以评估化疗前血清CA125浓度及其在诱导治疗期间的半衰期的预后价值。分析的终点是进展率和至进展时间。如果按肿瘤大小分层，化疗前CA 125水平无预后价值（P= 0.36）。然而，CA125的半衰期是一个独立的预后变量（P= 0.01）。与半衰期小于20天的患者的43个月相比，半衰期大于等于20天的患者的进展率高3.2倍，中位进展时间显著缩短，仅为11个月。
Eighty-five patients with epithelial ovarian cancer were studied to assess the prognostic value of the prechemotherapy serum concentration of CA125 and its half-life during induction therapy. The endpoints of the analysis were progression rate and time to progression. The prechemotherapy CA125 level had no prognostic value (P= 0.36) if the patients were stratified for tumor size. The half-life of CA125, however, was an independent prognostic variable (P= 0.01). Patients with a half-life of 20 days and more had a 3.2 times higher progression rate and a significantly shorter median time to progression of only 11 months, as compared to 43 months for patients with a half-life of less than 20 days.